Tyra Biosciences, Inc.
TYRA
$20.92
$0.110.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.09% | 35.45% | 39.05% | 38.43% | 25.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.87% | 27.45% | 29.34% | 30.34% | 44.37% |
| Operating Income | -25.87% | -27.45% | -29.34% | -30.34% | -44.37% |
| Income Before Tax | -33.37% | -30.86% | -27.82% | -25.09% | -41.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.37% | -30.86% | -27.82% | -25.09% | -41.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.37% | -30.86% | -27.82% | -25.09% | -41.46% |
| EBIT | -25.87% | -27.45% | -29.34% | -30.34% | -44.37% |
| EBITDA | -25.92% | -27.45% | -29.31% | -30.27% | -44.39% |
| EPS Basic | -17.01% | -5.63% | 3.00% | 6.72% | -15.51% |
| Normalized Basic EPS | -17.02% | -5.63% | 3.02% | 6.73% | -15.50% |
| EPS Diluted | -17.01% | -5.63% | 3.00% | 6.72% | -15.51% |
| Normalized Diluted EPS | -17.02% | -5.63% | 3.02% | 6.73% | -15.50% |
| Average Basic Shares Outstanding | 11.70% | 20.38% | 30.60% | 33.96% | 25.10% |
| Average Diluted Shares Outstanding | 11.70% | 20.38% | 30.60% | 33.96% | 25.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |